PSTX has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
PSTX has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Warning Sign:
Piotroski F-Score of 1 is low, which usually implies poor business operation.
The zones of discrimination were as such:
Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3
Poseida Therapeutics has an F-score of 1. It is a bad or low score, which usually implies poor business operation.
The historical rank and industry rank for Poseida Therapeutics's Piotroski F-Score or its related term are showing as below:
During the past 7 years, the highest Piotroski F-Score of Poseida Therapeutics was 5. The lowest was 1. And the median was 4.
The historical data trend for Poseida Therapeutics's Piotroski F-Score can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Poseida Therapeutics Annual Data | ||||||||||||||||
Trend | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||
Piotroski F-Score | Get a 7-Day Free Trial | N/A | 4.00 | 5.00 | 4.00 | 2.00 |
Poseida Therapeutics Quarterly Data | ||||||||||||||||||||
Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | |
Piotroski F-Score | Get a 7-Day Free Trial | 5.00 | 5.00 | 2.00 | 2.00 | 1.00 |
For the Biotechnology subindustry, Poseida Therapeutics's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Poseida Therapeutics's Piotroski F-Score distribution charts can be found below:
* The bar in red indicates where Poseida Therapeutics's Piotroski F-Score falls into.
How is the Piotroski F-Score calculated?
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
This Year (Mar24) TTM: | Last Year (Mar23) TTM: |
Net Income was -27.456 + -31.778 + -25.349 + -24.274 = $-108.86 Mil. Cash Flow from Operations was -33.306 + 7.888 + -28.744 + -15.135 = $-69.30 Mil. Revenue was 20.013 + 9.352 + 24.995 + 28.142 = $82.50 Mil. Gross Profit was 20.013 + 9.352 + 24.995 + 28.142 = $82.50 Mil. Average Total Assets from the begining of this year (Mar23) to the end of this year (Mar24) was (313.621 + 281.215 + 302.252 + 273.885 + 262.58) / 5 = $286.7106 Mil. Total Assets at the begining of this year (Mar23) was $313.62 Mil. Long-Term Debt & Capital Lease Obligation was $78.57 Mil. Total Current Assets was $216.73 Mil. Total Current Liabilities was $84.76 Mil. |
Net Income was -43.036 + 70.409 + -33.318 + -38.847 = $-44.79 Mil. Revenue was 2.7 + 116.306 + 10.051 + 10.343 = $139.40 Mil. Gross Profit was 2.7 + 116.306 + 10.051 + 10.343 = $139.40 Mil. Average Total Assets from the begining of last year (Mar22) to the end of last year (Mar23) was (248.152 + 205.455 + 380.481 + 351.837 + 313.621) / 5 = $299.9092 Mil. Total Assets at the begining of last year (Mar22) was $248.15 Mil. Long-Term Debt & Capital Lease Obligation was $82.07 Mil. Total Current Assets was $260.70 Mil. Total Current Liabilities was $48.69 Mil. |
*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.
Profitability
Question 1. Return on Assets (ROA)
Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.
Score 1 if positive, 0 if negative.
Poseida Therapeutics's current Net Income (TTM) was -108.86.
==> Negative ==> Score 0.
Question 2. Cash Flow Return on Assets (CFROA)
Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.
Score 1 if positive, 0 if negative.
Poseida Therapeutics's current Cash Flow from Operations (TTM) was -69.30.
==> Negative ==> Score 0.
Question 3. Change in Return on Assets
Compare this year's return on assets (1) to last year's return on assets.
Score 1 if it's higher, 0 if it's lower.
ROA (This Year) | = | Net Income | / | Total Assets (Mar23) |
= | -108.857 | / | 313.621 | |
= | -0.34709729 |
ROA (Last Year) | = | Net Income | / | Total Assets (Mar22) |
= | -44.792 | / | 248.152 | |
= | -0.18050227 |
Poseida Therapeutics's return on assets of this year was -0.34709729. Poseida Therapeutics's return on assets of last year was -0.18050227.
==> Last year is higher ==> Score 0.
Question 4. Quality of Earnings (Accrual)
Compare Cash flow return on assets (2) to return on assets (1)
Score 1 if CFROA > ROA, 0 if CFROA <= ROA.
Poseida Therapeutics's current Net Income (TTM) was -108.86. Poseida Therapeutics's current Cash Flow from Operations (TTM) was -69.30.
==> -69.30 > -108.86 ==> CFROA > ROA ==> Score 1.
Funding
Question 5. Change in Gearing or Leverage
Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.
Score 0 if this year's gearing is higher, 1 otherwise.
Gearing (This Year: Mar24) | = | Long-Term Debt & Capital Lease Obligation | / | Average Total Assets from Mar23 to Mar24 |
= | 78.566 | / | 286.7106 | |
= | 0.27402545 |
Gearing (Last Year: Mar23) | = | Long-Term Debt & Capital Lease Obligation | / | Average Total Assets from Mar22 to Mar23 |
= | 82.068 | / | 299.9092 | |
= | 0.27364282 |
Poseida Therapeutics's gearing of this year was 0.27402545. Poseida Therapeutics's gearing of last year was 0.27364282.
==> Last year is lower than this year ==> Score 0.
Question 6. Change in Working Capital (Liquidity)
Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.
Score 1 if this year's current ratio is higher, 0 if it's lower
Current Ratio (This Year: Mar24) | = | Total Current Assets | / | Total Current Liabilities |
= | 216.732 | / | 84.763 | |
= | 2.55691752 |
Current Ratio (Last Year: Mar23) | = | Total Current Assets | / | Total Current Liabilities |
= | 260.696 | / | 48.69 | |
= | 5.35420004 |
Poseida Therapeutics's current ratio of this year was 2.55691752. Poseida Therapeutics's current ratio of last year was 5.35420004.
==> Last year's current ratio is higher ==> Score 0.
Question 7. Change in Shares in Issue
Compare the number of shares in issue this year, to the number in issue last year.
Score 0 if there is larger number of shares in issue this year, 1 otherwise.
Poseida Therapeutics's number of shares in issue this year was 96.02. Poseida Therapeutics's number of shares in issue last year was 86.265.
==> There is larger number of shares in issue this year. ==> Score 0.
Efficiency
Question 8. Change in Gross Margin
Compare this year's gross margin (Gross Profit divided by sales) to last year's.
Score 1 if this year's gross margin is higher, 0 if it's lower.
Gross Margin (This Year: TTM) | = | Gross Profit | / | Revenue |
= | 82.502 | / | 82.502 | |
= | 1 |
Gross Margin (Last Year: TTM) | = | Gross Profit | / | Revenue |
= | 139.4 | / | 139.4 | |
= | 1 |
Poseida Therapeutics's gross margin of this year was 1. Poseida Therapeutics's gross margin of last year was 1.
==> Last year's gross margin is higher ==> Score 0.
Question 9. Change in asset turnover
Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.
Score 1 if this year's asset turnover ratio is higher, 0 if it's lower
Asset Turnover (This Year) | = | Revenue | / | Total Assets at the Beginning of This Year (Mar23) |
= | 82.502 | / | 313.621 | |
= | 0.26306274 |
Asset Turnover (Last Year) | = | Revenue | / | Total Assets at the Beginning of Last Year (Mar22) |
= | 139.4 | / | 248.152 | |
= | 0.56175247 |
Poseida Therapeutics's asset turnover of this year was 0.26306274. Poseida Therapeutics's asset turnover of last year was 0.56175247.
==> Last year's asset turnover is higher ==> Score 0.
Evaluation
Piotroski F-Score | = | Que. 1 | + | Que. 2 | + | Que. 3 | + | Que. 4 | + | Que. 5 | + | Que. 6 | + | Que. 7 | + | Que. 8 | + | Que. 9 |
= | 0 | + | 0 | + | 0 | + | 1 | + | 0 | + | 0 | + | 0 | + | 0 | + | 0 | |
= | 1 |
Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3
Poseida Therapeutics has an F-score of 1. It is a bad or low score, which usually implies poor business operation.
Poseida Therapeutics (NAS:PSTX) Piotroski F-Score Explanation
The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.
He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.
In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).
He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.
What he found was something that exceeded his most optimistic expectations.
Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.
Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).
Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.
Thank you for viewing the detailed overview of Poseida Therapeutics's Piotroski F-Score provided by GuruFocus.com. Please click on the following links to see related term pages.
John P. Schmid | director | 6310 NANCY RIDGE DRIVE, SUITE 101, SAN DIEGO CA 92121 |
Luke Corning | director | 614 DAVIS STREET, EVANSTON IL 60201 |
Marcea Bland Lloyd | director | 9360 TOWNE CENTRE DRIVE, SUITE 110, SAN DIEGO CA 92121 |
Charles M Baum | director | C/O MIRATI THERAPEUTICS INC., 9393 TOWNE CENTRE DRIVE, STE 200, SAN DIEGO CA 92121 |
Cynthia Collins | director | 65 WEST WATKINS MILL ROAD, GAITHERSBURG MD 20878 |
Rafael Amado | director | 210 EAST GRAND AVE, SOUTH SAN FRANCISCO CA 94080 |
Kristin Yarema | officer: President, Cell Therapy | C/O ATARA BIOTHERAPEUTICS, INC., 611 GATEWAY BLVD., SUITE 900, SOUTH SAN FRANCISCO CA 94080 |
Malin Life Sciences Holdings Ltd | 10 percent owner | 2 HARBOUR SQUARE, CROFTON ROAD, DUN LAOGHAIRE, CO, DUBLIN L2 ---- |
Eric Ostertag | director, 10 percent owner, officer: Chief Executive Officer | C/O POSEIDA THERAPEUTICS, INC., 4242 CAMPUS POINT COURT, SUITE 700, SAN DIEGO CA 92121 |
Kerry D. Ingalls | officer: Chief Operating Officer | C/O POSEIDA THERAPEUTICS, INC., 9390 TOWNE CENTRE DRIVE, SUITE 200, SAN DIEGO CA 92121 |
Brent Warner | officer: President, Gene Therapy | C/O POSEIDA THERAPEUTICS, INC., 9390 TOWNE CENTRE DRIVE, SUITE 200, SAN DIEGO CA 92121 |
Matthew A. Spear | officer: Chief Medical Officer | C/O POSEIDA THERAPEUTICS, INC., 4242 CAMPUS POINT COURT, SUITE 700, SAN DIEGO CA 92121 |
Harry J Leonhardt | officer: GC & Chief Compliance Officer | C/O HALOZYME THERAPEUTICS, INC., 11388 SORRENTO VALLEY BLVD., SAN DIEGO CA 92121 |
David Hirsch | director | C/O LONGITUDE CAPITAL PARTNERS, LLC, 800 EL CAMINO REAL, SUITE 220, MENLO PARK CA 94025 |
Sean Murphy | director, 10 percent owner | C/O NOVAN, INC., 4222 EMPEROR BOULEVAND, SUITE 200, DURHAM NC 27703 |
From GuruFocus
By PRNewswire PRNewswire • 05-23-2023
By PRNewswire PRNewswire • 12-06-2022
By PRNewswire PRNewswire • 05-22-2023
By PRNewswire • 11-14-2023
By PRNewswire PRNewswire • 06-01-2023
By PRNewswire • 11-14-2023
By PRNewswire • 07-05-2023
By PRNewswire PRNewswire • 05-18-2023
By PRNewswire • 08-07-2023
By PRNewswire PRNewswire • 02-08-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.